Tampa, Florida, United States – The Newswire – October 29, 2024 – The CEO of CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) attended a joint meeting for Advancing Smoking Cessation held by the FDA and NIH. Attendance from this meeting included people from the FDA, NIH, Scientists, Doctors, and Professors that have spent their lives understanding the effects of smoking and tobacco/nicotine addiction. The purpose of this meeting was to advance technology for smoking cessation.

The CEO of CTT Pharma, Ryan Khouri stated, I had the opportunity to speak at this FDA/NIH meeting and personally met with many individuals who work for both the FDA and NIH. I learned that CTT Pharma qualifies for additional grants and will begin working immediately with our team to achieve approval of these grants for smoking cessation. CTT Pharma’s patented dissolvable nicotine strips are a viable solution to a worldwide problem and should be used as a tool to get people to stop smoking. I look forward to working with the government and developing our innovative technology to combat the tobacco epidemic.  I want to repeat the following again, The World Health Organization states, “The tobacco epidemic is one of the biggest public health threats the world has ever faced, killing over 8 million people a year around the world. More than 7 million of those deaths are results of direct tobacco use while 1.3 million are the result of non-smokers being exposed to second-hand smoke.”  The CDC says, “Cigarette smoking is the leading cause of preventable death in the United States. Cigarette smoking causes more than 480,000 deaths each year in the United States. This is nearly one in five deaths.”

CTT Pharma will continue to update shareholders as more information becomes available.

 

CTT Pharma – 813-606-0060